Journals / MN Kardiyoloji / 2006 / Cilt: 13 - Sayı: 1

Pulmonary hypertension and the role of prostacyclin and its analogues in treatment

Pulmoner hipertansiyon ve prostasiklin analoglarının tedavideki yeri

Pages
61–78
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mech­anism of prostacyclin action, the long-term effects of the prostacyclin therapy, prostacyclin analogues and the in­terac­tion with other potent vasodilatators and their role in the treatment of pulmonary arteial hypertension are in­ves­tigated fastidiously.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prostacyclin and its analogues (prostanoids) have antithrombotic and antiproliferative properties beside their potent va­sodilatory effect.
📊
Key Findings & Data:Because of these properties, even the mechanism underlying the benefical effects remain un­known, prostacyclin and prostanoids have a prominent role in the treatment of pulmonary arterial hypertension.
💡
Conclusion & Impact:The mech­anism of prostacyclin action, the long-term effects of the prostacyclin therapy, prostacyclin analogues and the in­terac­tion with other potent vasodilatators and their role in the treatment of pulmonary arteial hypertension are in­ves­tigated fastidiously.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Hipertansiyon · pulmoner · Epoprostenol

Abstract

Prostacyclin and its analogues (prostanoids) have antithrombotic and antiproliferative properties beside their potent va­sodilatory effect. Because of these properties, even the mechanism underlying the benefical effects remain un­known, prostacyclin and prostanoids have a prominent role in the treatment of pulmonary arterial hypertension. In this review article, the classification, etiology and pathogenesis of pulmonary arterial hypertension is discussed in de­tail and the symptoms, physical examination findings and the methods for diagnosis are reviewed. The mech­anism of prostacyclin action, the long-term effects of the prostacyclin therapy, prostacyclin analogues and the in­terac­tion with other potent vasodilatators and their role in the treatment of pulmonary arteial hypertension are in­ves­tigated fastidiously.

Özet

Pro­stasiklin ve analogları (prostanoidler), güçlü vazodilatör özelliklerinin yanında antitrombotik ve antiproliferatif et­ki­lere sahiptirler. Bu özelliklerinden dolayı, yararlı etkilerinin altta yatan asıl mekanizması tam olarak anlaşılamamış ol­sa bile, pulmoner hipertansiyon tedavisinde önemli bir yer edinmişlerdir. Bu derlemede, pulmoner hi­per­tan­si­yo­nun çeşitli sınıflamaları, etyoloji ve patogenezi geniş bir biçimde ele alınmış; hastalığın semptomları, fizik muayene bul­guları ve tanı yöntemleri özetlenmiştir. Prostasiklin tedavisinin etki mekanizması ve uzun dönem sonuçları, pros­ta­siklin analogları ve bu ilaçların diğer güçlü vazodilatörler ile ilişkileri ve tedavide kullanımları ile ilgili son ge­liş­me­ler titizlikle incelenmiştir.

🔖

Cite This Article

BUDAK, B., TÜTÜN, U., KATIRCIOĞLU, S. F. (2006). Pulmonary hypertension and the role of prostacyclin and its analogues in treatment. MN Kardiyoloji, Cilt: 13 - Sayı: 1, 61–78. https://ajindex.com/articles/297546

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 397
  2. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet D03
  3. Fowler NO, Wescott RN, Scott RC. Normal pressure in right Bart and pulmonary artery. Am Heart J 1953
  4. Chatterjee K, De Marco T, Alpert JS. Pulmonary hpertension: Hemodynamic diagnosis and management, reives of Internal Medicine. Chicago: Sep 23, 2002. Vol. 162, Iss. 17
  5. Davidson WR Jr, Fee EC. Influence of aging on pulmonary emodynamics in a population.free of coronary artery disease, m JCardiol 1990
  6. Fernie J, Lamb D. Effects of age and smoking on intima of muscular pulmonary arteries. J Clin Pathol 1986
  7. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991
  8. Executive Summary from World Symposium on Primary Pulmonary Hypertension 1998. World Health Organization Web site. Available at: http://www.who.int /ncd/cvd/pph.html. Site verified 25, 2002. 9.Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987
  9. Abenheim L, Moride Y, Brenot F, et al. Appetite-supressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996
  10. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004
  11. Suppl S:13S-24S. 12.Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension. In: Rubin L, Rich S, eds. Primary pulmonary hypertension. New York: Marcel Dekker 1997:83-129. 13.Olschewski H, Rose F, Schermuly H, et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacology & Therapeutics 2004
  12. Jeffery TK, Morrell NW. Molecular and celular basis of pulmonary vascular remodelling in pulmonary hypertension. Prog Cardiovasc Dis 2002: 45
  13. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987: 76
  14. Pietra G. Histopathology of primary pulmonary hypertension. Chest 1994: 105
  15. 2S-6S. 17.Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J